AT383358T - 5-phenylthiazolderivate and their use as p13 kinase inhibitors - Google Patents

5-phenylthiazolderivate and their use as p13 kinase inhibitors

Info

Publication number
AT383358T
AT383358T AT04717567T AT04717567T AT383358T AT 383358 T AT383358 T AT 383358T AT 04717567 T AT04717567 T AT 04717567T AT 04717567 T AT04717567 T AT 04717567T AT 383358 T AT383358 T AT 383358T
Authority
AT
Austria
Prior art keywords
phenylthiazolderivate
use
kinase inhibitors
p13 kinase
p13
Prior art date
Application number
AT04717567T
Other languages
German (de)
Inventor
G C Bloomfield
Ian Bruce
Catherine Leblanc
Mrinalini S Oza
Lewis Whitehead
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB0305152A priority Critical patent/GB0305152D0/en
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Publication of AT383358T publication Critical patent/AT383358T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
AT04717567T 2003-03-06 2004-03-05 5-phenylthiazolderivate and their use as p13 kinase inhibitors AT383358T (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0305152A GB0305152D0 (en) 2003-03-06 2003-03-06 Organic compounds

Publications (1)

Publication Number Publication Date
AT383358T true AT383358T (en) 2008-01-15

Family

ID=9954250

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04717567T AT383358T (en) 2003-03-06 2004-03-05 5-phenylthiazolderivate and their use as p13 kinase inhibitors

Country Status (14)

Country Link
US (1) US8017608B2 (en)
EP (1) EP1608647B1 (en)
JP (1) JP4382085B2 (en)
CN (1) CN100569770C (en)
AT (1) AT383358T (en)
AU (1) AU2004218239B2 (en)
BR (1) BRPI0408068A (en)
CA (1) CA2517708A1 (en)
DE (1) DE602004011199T2 (en)
ES (1) ES2297393T3 (en)
GB (1) GB0305152D0 (en)
MX (1) MXPA05009468A (en)
PT (1) PT1608647E (en)
WO (1) WO2004078754A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
SE0402735D0 (en) * 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
US7799814B2 (en) 2005-05-24 2010-09-21 Merck Serono S.A. Thiazole derivatives and use thereof
UA92489C2 (en) * 2005-05-24 2010-11-10 Лаборатуар Сероно С.А. Thiazole derivatives and use thereof
JP2008543754A (en) * 2005-06-09 2008-12-04 メルク エンド カムパニー インコーポレーテッドMerck & Company Incoporated Checkpoint kinase inhibitor
UA100358C2 (en) 2005-08-26 2012-12-25 Мерк Сероно Са Pyrazine derivatives and their use
GB2431156A (en) * 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
JP2009523769A (en) * 2006-01-23 2009-06-25 ラボラトワール セローノ ソシエテ アノニム Thiazole derivatives and use of these
EP2016075A1 (en) * 2006-05-03 2009-01-21 AstraZeneca AB Thiazole derivatives and their use as anti-tumour agents
GB0608854D0 (en) * 2006-05-04 2006-06-14 Chroma Therapeutics Ltd P13 kinase inhibitors
CN101528738A (en) * 2006-09-01 2009-09-09 沃泰克斯药物股份有限公司 5-(2-furyl)-1,3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase
GB0620059D0 (en) 2006-10-10 2006-11-22 Ucb Sa Therapeutic agents
GB0620818D0 (en) * 2006-10-19 2006-11-29 Ucb Sa Therapeutic agents
WO2008101979A1 (en) 2007-02-22 2008-08-28 Merck Serono S.A. Quinoxaline compounds and use thereof
EP2581081A3 (en) 2007-06-01 2013-07-31 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
GB0719644D0 (en) * 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
ES2437595T3 (en) 2007-12-20 2014-01-13 Novartis Ag Thiazole derivatives used as inhibitors of PI 3 kinase
MY151556A (en) 2008-09-10 2014-06-13 Novartis Ag Organic compounds
WO2010045303A2 (en) * 2008-10-16 2010-04-22 Schering Corporation Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
JP5667086B2 (en) 2009-02-12 2015-02-12 メルク セローノ ソシエテ アノニム 2-morpholino - pyrido [3,2-d] pyrimidine
KR20120046723A (en) 2009-07-02 2012-05-10 노파르티스 아게 2-carboxamide cycloamino ureas useful as pi3k inhibitors
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
EP3444242A3 (en) * 2009-11-05 2019-03-20 Rhizen Pharmaceuticals S.A. Novel benzopyran kinase modulators
KR20130049766A (en) 2009-11-13 2013-05-14 메르크 세로노 에스. 에이. Tricyclic pyrazol amine derivatives
KR20120123513A (en) 2010-02-03 2012-11-08 시그날 파마소티칼 엘엘씨 IDENTIFICATION OF LKBl MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS
US9255072B2 (en) * 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
AU2012250576B2 (en) * 2011-05-04 2017-04-27 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinases
CN103857804A (en) 2011-08-03 2014-06-11 西格诺药品有限公司 Identification of gene expression profile as a predictive biomarker for lkb1 status
CN102633748A (en) * 2012-03-22 2012-08-15 盛世泰科生物医药技术(苏州)有限公司 Method for synthesizing 2-ethyl formate-5-bromine-1,3,4-thiadiazole
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CN105339008A (en) 2013-04-17 2016-02-17 西格诺药品有限公司 Combination therapy comprising tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
MX2015014590A (en) 2013-04-17 2016-03-03 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines.
JP6382945B2 (en) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ,エルエルシー Dihydropyrazino - cancer treatment with pyrazine
CN105339009B (en) 2013-04-17 2018-08-28 西格诺药品有限公司 For the treatment of cancer including tor kinase inhibitor and 5-substituted quinazolinone compounds of the combination therapy
EP2986321A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
NZ629469A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
KR20160004273A (en) 2013-04-17 2016-01-12 시그날 파마소티칼 엘엘씨 PHARMACEUTICAL FORMULATIONS, PROCESSES, SOLID FORMS AND METHODS OF USE RELATING TO 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO[2,3-b]PYRAZIN-2(1H)-ONE
CN109503591A (en) 2013-05-29 2019-03-22 西格诺药品有限公司 Pharmaceutical composition, its solid form and their purposes of dihydro pyrazine and pyrazine compound
NZ629866A (en) 2014-04-16 2015-12-24 Signal Pharm Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, and a coformer, compositions and methods of use thereof
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US20190062323A1 (en) * 2016-02-26 2019-02-28 The Board Of Trustees Of The Leland Stanford Junior University PI-Kinase Inhibitors with Anti-Infective Activity
AU2017331940A1 (en) * 2016-09-22 2019-05-02 Astrazeneca Ab 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1 H-isoindol-1 -one derivatives and their use as dual inhibitors of phosphatidylinositol 3-kinase delta & gamma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT309241T (en) 1999-09-10 2005-11-15 Merck & Co Inc Tyrosine kinase inhibitors
DK1257537T3 (en) * 2000-01-24 2007-10-01 Astrazeneca Ab Therapeutic morpholino-substituted compounds
MY156407A (en) 2002-02-28 2016-02-26 Novartis Ag 5-phenylthiazole derivatives and use as p13 kinase inhibitors

Also Published As

Publication number Publication date
US8017608B2 (en) 2011-09-13
CA2517708A1 (en) 2004-09-16
AU2004218239B2 (en) 2007-02-22
EP1608647A1 (en) 2005-12-28
AU2004218239A1 (en) 2004-09-16
EP1608647B1 (en) 2008-01-09
GB0305152D0 (en) 2003-04-09
JP2006515343A (en) 2006-05-25
CN100569770C (en) 2009-12-16
JP4382085B2 (en) 2009-12-09
CN1780832A (en) 2006-05-31
DE602004011199D1 (en) 2008-02-21
DE602004011199T2 (en) 2009-01-02
MXPA05009468A (en) 2006-02-13
US20060148822A1 (en) 2006-07-06
WO2004078754A1 (en) 2004-09-16
PT1608647E (en) 2008-03-27
BRPI0408068A (en) 2006-02-14
ES2297393T3 (en) 2008-05-01

Similar Documents

Publication Publication Date Title
DE60334651D1 (en) Nicotinamide and their use as inhibitors of P38
DE69928286D1 (en) Benzenesulfonamid-derivative and their use as inhibitors mek
DE60316810D1 (en) 2- (3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
AT494991T (en) Klammernachfüllvorrichtung, stapler and cartridge
AT532772T (en) Piperazine derivatives and their use as therapeutic agents
NO20043162L (en) quinazoline
DE602004030689D1 (en) Compounds against inflammation and immune-related uses
AT420861T (en) 2-pyridone derivatives as inhibitors of neutrophil elastase and their use
DE602004011683D1 (en) Approval procedure for
DE60324909D1 (en) (20s) -1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor vitamin D3 and their use
DE60230868D1 (en) Criptoblockierende antibodies and their use
AT412642T (en) Inhibitors of p-38 kinase
DE60231549D1 (en) Stabilized reverse-micelle-compositions and their use
NL1025404A1 (en) Pyrazolo-triazine compounds and their use.
DE60329910D1 (en) benzazoles substituted and their use as raf kinase inhibitors
DE50306232D1 (en) Ampholytic copolymer and its use
DE60312525D1 (en) Biosynthetic matrix and their use
AT517992T (en) Functional and Hyperfunctional sirna
AT7708U3 (en) Holster and sicherheitsabdeckeinrichtung
DE60142921D1 (en) Azaphenanthridone derivatives and their use as PARP inhibitors
NO20044095L (en) 5-fenyltiazolderivater and use as P13 kinase inhibitors
AT345683T (en) Malonsäuerenitril-compounds and their use as pesticides
DE602004014969D1 (en) 1h-imidazochinolinderivate as protein kinase inhibitors
DE602005013922D1 (en) Condensed heterotetracyclische compounds and their use as HCV-polymerase-inhibitor
DE60300647D1 (en) Lighting device and its use

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1608647

Country of ref document: EP